Targets › LY6E
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2028.
GPI-anchored cell surface protein that regulates T-lymphocytes proliferation, differentiation, and activation. Regulates the T-cell receptor (TCR) signaling by interacting with component CD3Z/CD247 at the plasma membrane, leading to CD3Z/CD247 phosphorylation modulation (By similarity). (UniProt, Q16553)
Open in Phaseline: the race on LY6E, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Merck KGaA | M7437 anti-Ly6E antibody-drug conjugate with exatecan payload | LY6E | Phase 1 | Advanced Solid Tumors | Sep 2028 |
Advanced Solid Tumors (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.